5 billion people have access to medicine 2 billion to go


The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Who we are
What we analyse
How we drive change

New online: the case for fixing the global antibiotic market

White Paper on Antibiotic Shortages, Stockouts and Scarcity

This new white paper unpacks why antibiotic supply chains are failing and how this will have a global impact on basic healthcare. It makes the case for fixing the antibiotic market through coordinated action by governments, regulators and industry.

First Japanese asset owner signs the Foundation’s investor statement

14 Sep 2018
The first Japanese asset owner signs the Access to Medicine Foundation's investor statement, becoming the 73rd signatory to pledge support to the Foundation's research.

Foundation to convene high-level meeting in Mumbai on access to medicine and AMR

28 Aug 2018
The Access to Medicine Foundation will be visiting Mumbai, India, this week for a one-day meeting with pharmaceutical companies to discuss strategies to improve access to medicine and combat AMR.

New paper explains expanded Index focus on global health R&D

03 Aug 2018
The 2018 Index newly covers all diseases identified as priority targets for global health R&D, as set out in a new article published in Health Research Policy and Systems.

Data analysis gathers pace for 2018 Access to Medicine Index

02 Aug 2018
Scoring for the 6th Access to Medicine Index is now complete. Trend analysis is underway and the team is identifying best practices and opportunities.

Index added to new online toolbox for impact investors

13 Jul 2018
The Access to Medicine Index and AMR Benchmark have been added to Navigating Impact, a new online resource center developed specifically for impact investors. This is the latest example of the Foundation’s research and metrics being integrated into investor platforms, following the Bloomberg Terminal and the Sustainability Accounting Standards Board.

Experts gather to discuss proposals for 2020 Antimicrobial Resistance Benchmark

27 Jun 2018
The Expert Committee for the AMR Benchmark meets in Amsterdam on July 2. The agenda is topped by targeted proposals for refining the Benchmark methodology for 2020.

Access to Medicine Index gains first Japanese signatory investor

08 Jun 2018
Sumitomo Mitsui Trust Holdings is the latest investor to publicly endorse the Access to Medicine Index, becoming the 68th signatory to the Index investor statement. The Tokyo-based company manages assets of USD 497 billion.

Access to Medicine Foundation makes case for fixing the antibiotic market

31 May 2018
Today, the Access to Medicine Foundation warns that antibiotic supply chains are on the brink of collapse, putting basic healthcare at risk, in a new white paper titled “Shortages, stockouts and scarcity: the issues facing the security of antibiotic supply and the role for pharmaceutical companies”. Urgent action is needed to rebuild the antibiotics market. The paper shows how some pharmaceutical companies are responding.

Work starts on metrics for the 2020 AMR Benchmark

19 Apr 2018
The Access to Medicine Foundation has started the methodology review for the next Antimicrobial Resistance Benchmark. The Foundation is consulting a wide range of experts and stakeholders to explore how to refine its analysis of pharmaceutical company responses to antimicrobial resistance.

Access to Medicine Foundation in India to discuss AMR strategies

12 Mar 2018
India is home to more than a billion people, who face increasing rates of drug resistance. From 12-16 March, the Access to Medicine Foundation will be in New Delhi and Mumbai, India, to meet with Indian-based pharmaceutical companies and government representatives to share ideas and opportunities to limit drug resistance. The Foundation’s Executive Director, Jayasree K. Iyer, will also speak at the Delhi End TB Summit.
Access to Medicine Index Cover

Access to Medicine Index 2016

The only in-depth comparison of the world’s largest pharma companies on how they improve access to medicine for the poor.

Visit website

Access to Vaccines Index Cover

Access to Vaccines Index 2017

The first tool to show how vaccine companies are responding to calls to increase access to vaccines.

Visit website

Antimicrobial Resistance Benchmark 2018

The first detailed analysis of pharmaceutical company action against antimicrobial resistance.

Visit website

We’re hiring!

Interested in working toward the next AMR Benchmark ?
The Foundation is looking for an experienced Research Programme Manager to manage the team developing the AMR Benchmark.


Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.

The foundation on Twitter

Access to Medicine's Twitter avatar
Access to Medicine

Next week, our Researcher Beth Boyer (@bethboyermph) will discuss #pharma co.s actions to improve #access to… t.co/GOqZ48u7Kj

Access to Medicine's Twitter avatar
Access to Medicine

#Applynow: We are looking for an experienced Research Programme Managger to join the #research team in charge of de… t.co/fZCFWKJwkt

Access to Medicine's Twitter avatar
Access to Medicine

"It’s important that biologics and biosimilar manufacturers realize that the U.S., EU, and Japanese markets are not… t.co/96gRNcknJC

Josefien Knoeff's Twitter avatar
Josefien Knoeff

Glad I could share insights from the #amrbenchmark on #pharma's role in curbing #AMR at the 'Tackling… t.co/n0Rt4RJ9y7

Retweeted by Access to Medicine
Access to Medicine's Twitter avatar
Access to Medicine

Today, London: Our @JosefienKnoeff presents #AMRBenchmark2018 & its key findings on #pharma co.s action to curb… t.co/Zh1W3Gb6YU

Encourage pharma companies Access to Medicine


Incentivising pharma to develop medicine for the poor
Which mechanisms work for engaging pharma companies in R&D for diseases of poverty?

“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.


Embedding pro-access governance


Mainstreaming inclusive business models


Improving industry responsiveness to public health priorities


Employing ‘access-thinking’ in product deployment


Addressing unmet needs through R&D

The Access to Medicine Foundation and its publications are funded by